Product Name

Brivaracetam

Name: Brivaracetam
SKU: 357336-20-0

CAS Number

357336-20-0

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Brivaracetam

CAS Number:

357336-20-0

Indication:

Brivaracetam is indicated for adults and children ages one month and older as therapy for epilepsy, specifically partial-onset seizures.

Mode of Action:

Clearance of Brivaracetam may be reduced in patients with hepatic insufficiency, however the photo paroxysmal response model in patients diagnosed with photosensitive epilepsy has proven to be effective.

Pharmacodynamics:

Brivaracetam is chemically related to the AED Levetiracetam and possesses a natural binding affinity for the 2A synaptic vesicle protein. A higher potency in suppressing epileptiform responses in vitro, roughly ten-fold above that of Levetiracetam, has been shown in comprehensive studies of Brivaracetam. The ability of Brivaracetam to suppress various seizure types in studies, including genetic forms of epilepsy in patients offers patients a novel inhibitory therapy.

Metabolism:

Brivaracetam has a half-life of eight hours and virtually complete bioavailability. As Brivaracetam is mainly metabolized via hydrolysis of the acetamide group, as well as CYP2C8-mediated hydroxylation, its metabolites are not pharmacologically active.

Toxicity:

Brivaracetam has been tested in a comprehensive trials for toxicology, safety and genotoxicity. A low acute toxicity has been found in patients who received therapy with Brivaracetam. Commonly reported adverse effects have been documented as mild, and include fatigue, dizziness, headache and somnolence.

IUPAC:

1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS, 4R)-

PubChem:

9837243

Formula:

C11-H20-N2-O2

Molecular Mass:

212.291

Synonyms:

(2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, Brivaracetam, UCB 34714, UCB34714, UNII-U863JGG2IA

SMILES:

CCC[C@@H]1CC(=O)[N@@](C1)C(CC)C(=O)N

InChi:

1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9?/m1/s1

General Reference:

von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007 Jan;4(1):84-7.
Br J Pharmacol. 2008 Aug; 154(8): 1555–1557.
Alzheimers Res Ther. 2015 May 5;7(1):25. doi: 10.1186/s13195-015-0110-9. eCollection 2015.
Ryvlin, P., et al., Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia, 2014. 55(1):47-56.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

LGM pharma’s unique mix of API sourcing and CDMO services is fueling robust growth

Brivaracetam

357336-20-0

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product